Interferon beta-1a in children with multiple sclerosis is well tolerated

被引：67

作者：

Waubant, E ^{[1
]}

Hietpas, J ^{[1
]}

Stewart, T ^{[1
]}

Dyme, Z ^{[1
]}

Herbert, J ^{[1
]}

Lacy, J ^{[1
]}

Miller, C ^{[1
]}

Rensel, M ^{[1
]}

Schwid, S ^{[1
]}

Goodkin, D ^{[1
]}

机构：

[1] USCF, Mt Zion Multiple Sclerosis Ctr, San Francisco, CA USA

来源：

NEUROPEDIATRICS | 2001年 / 32卷 / 04期

关键词：

multiple sclerosis; interferon beta; children;

D O I：

10.1055/s-2001-17370

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults. Objective: To determine the tolerability of interferon beta-1a (IFNB-1a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS). Design/Methods: A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1 a in patients younger than 16 years. Results: Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1 a. Mean age on initiating treatment was 12.7 years (range 8-15) and mean duration of therapy was 17 months (range 5-36). No patient discontinued therapy due to an adverse event. Conclusions: Preliminary data indicate that weekly intramuscular injections of IFNB-1a are well tolerated.

引用

页码：211 / 213

页数：3

共 10 条

[1] Interferon beta-1b and childhood multiple sclerosis [J].

Adams, AB ;

Tyor, WR ;

Holden, KR .

PEDIATRIC NEUROLOGY, 1999, 21 (01) :481-483

[2]

[Anonymous], 1993, Multiple Sclerosis: a statistical portrait

[3] Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children [J].

Dale, RC ;

de Sousa, C ;

Chong, WK ;

Cox, TCS ;

Harding, B ;

Neville, BGR .

BRAIN, 2000, 123 :2407-2422

[4] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[5] MULTIPLE-SCLEROSIS IN CHILDHOOD - CLINICAL PROFILE IN 125 PATIENTS [J].

DUQUETTE, P ;

MURRAY, TJ ;

PLEINES, J ;

EBERS, GC ;

SADOVNICK, D ;

WELDON, P ;

WARREN, S ;

PATY, DW ;

UPTON, A ;

HADER, W ;

NELSON, R ;

AUTY, A ;

NEUFELD, B ;

MELTZER, C .

JOURNAL OF PEDIATRICS, 1987, 111 (03) :359-363

[6] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[7] COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

JOHNSON, KP ;

BROOKS, BR ;

COHEN, JA ;

FORD, CC ;

GOLDSTEIN, J ;

LISAK, RP ;

MYERS, LW ;

PANITCH, HS ;

ROSE, JW ;

SCHIFFER, RB ;

VOLLMER, T ;

WEINER, LP ;

WOLINSKY, JS ;

BIRD, SJ ;

CONSTANTINESCU, C ;

KOLSON, DL ;

GONZALEZSCARANO, F ;

BRENNAN, D ;

PFOHL, D ;

MANDLER, RN ;

ROSENBERG, GA ;

JEFFREY, C ;

BARGER, GR ;

GANDHI, B ;

MOORE, PM ;

ROGERS, LR ;

LISAK, D ;

SMITH, L ;

ELLISON, GW ;

BAUMHEFNER, RW ;

CRAIG, SL ;

JALBUT, SS ;

KATZ, E ;

CONWAY, KL ;

BURNS, JB ;

SHIBA, C ;

GIANG, DW ;

PETRIE, MD ;

GUARNACCIA, JB ;

ANDERSON, S ;

MCKEON, A ;

MCCARTHY, M ;

THOMAS, AB ;

VRIESENDORP, FJ ;

AUSTIN, SG ;

LINDSEY, JW ;

DIMACHKIE, M ;

CERRETA, E ;

KACHUCK, N ;

MCCARTHY, KA .

NEUROLOGY, 1995, 45 (07) :1268-1276

[8] Defining the clinical course of multiple sclerosis: Results of an international survey [J].

Lublin, FD ;

Reingold, SC .

NEUROLOGY, 1996, 46 (04) :907-911

[9] NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].

POSER, CM ;

PATY, DW ;

SCHEINBERG, L ;

MCDONALD, WI ;

DAVIS, FA ;

EBERS, GC ;

JOHNSON, KP ;

SIBLEY, WA ;

SILBERBERG, DH ;

TOURTELLOTTE, WW .

ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231

[10] Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial [J].

Sokal, EM ;

Conjeevaram, HS ;

Roberts, EA ;

Alvarez, F ;

Bern, EM ;

Goyens, P ;

Rosenthal, P ;

Lachaux, A ;

Shelton, M ;

Sarles, J ;

Hoofnagle, J .

GASTROENTEROLOGY, 1998, 114 (05) :988-995

← 1 →